Stock KTRA KINTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Real-time Estimate Cboe BZX
Other stock markets
 10:27:34 2024-04-23 am EDT 		5-day change 1st Jan Change
0.121 USD +5.86% Intraday chart for Kintara Therapeutics, Inc. +10.55% -30.19%
Apr. 03 Sector Update: Health Care Stocks Softer Late Afternoon MT
Apr. 03 Sector Update: Health Care MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
PR
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
BU
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Gainers
MT
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
PR
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
BU
Transcript : Kintara Therapeutics, Inc., TuHURA Biosciences, Inc. - M&A Call
TuHURA Biosciences, Inc. entered into a definitive agreement to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.
CI
TuHURA Biosciences, Inc. agreed to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.
CI
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
PR
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)
AQ
Kintara Therapeutics Continues to Evaluate Strategic Options
CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
PR
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
PR
Kintara Therapeutics, Inc. Announces Initiation of Rem-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
CI
Wall Street Set for Cautious Opening in Final Trading Day of a Bullish 2023
MT
Index Futures Edge Higher to End Mostly Positive Year on High Note
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KTRA Stock
  4. News Kintara Therapeutics, Inc.